Cancer treatment and research communications最新文献

{"title":"Targeted therapy for non-small cell lung cancer (NSCLC) in a real-world setting: A single practice experience","authors":"Achim Rothe ,&nbsp;Nathalie Bauer ,&nbsp;Lutz Dietze ,&nbsp;Dieter Mainka ,&nbsp;Sonja Lehnert ,&nbsp;Matthias Scheffler","doi":"10.1016/j.ctarc.2025.100891","DOIUrl":"10.1016/j.ctarc.2025.100891","url":null,"abstract":"<div><div>Targeted treatment of non-small cell lung cancer (NSCLC) with driver aberrations has drastically improved the outcome of a subset of patients. However, for successful adaptation in the clinical routine, many stakeholders are involved, like comprehensive cancer centers, molecular pathology, peripheral hospitals, and oncology practices. Here, we present a single center experience in personalized treatment of lung cancer in Germany. Patients with advanced NSCLC and the need for systemic treatment after identification of a targetable driver mutation have been included in this analysis. Detection of the mutations was performed within a diagnostical network. Treatment was chosen depending on the respective driver mutation. We identified 58 patients (26 male, 32 female) with treatment relevant driver mutations: 33 patients (56.9 %) had an <em>EGFR</em> mutation, nine patients (15.5 %) presented with <em>ALK</em> translocation, five patients (8.6 %) were detected to have <em>BRAF</em> mutations, four had <em>ROS1</em> translocations (6.9 %) and 8 patients had <em>MET</em> mutations (13.8 % each). In one patient, concomitant <em>BRAF</em> and <em>MET</em> amplifications were detected. 52 patients received targeted therapy. The median overall survival was 35.5 months (95 % CI, 18.0–52.9 months). 32 patients (64 %) received subsequent treatment after initiation of targeted therapy first-line. Our single-center experience demonstrates that advances in the field of targeted NSCLC therapy are quickly incorporated into clinical routine in Germany. Noteworthy, no new safety information was found.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100891"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada","authors":"William J Phillips ,&nbsp;Horia Marginean ,&nbsp;Mohammad Alrehaili ,&nbsp;Arwa Ahmed Abdelrahim ,&nbsp;Tim Asmis ,&nbsp;Mike Vickers ,&nbsp;Benjamin Yeung ,&nbsp;Bryan Lo ,&nbsp;Rachel Goodwin","doi":"10.1016/j.ctarc.2025.100896","DOIUrl":"10.1016/j.ctarc.2025.100896","url":null,"abstract":"<div><h3>Background</h3><div>BRAF V600E mutations are identified in 10 % of metastatic colorectal cancer (mCRC) cases. In this project, we evaluated the clinicopathologic features and natural history of patients with BRAF mutant (BRAF-mt) mCRC prior to era of BRAF targeted therapy.</div></div><div><h3>Methods</h3><div>This is a retrospective project evaluating patients with diagnosed with mCRC with an identified BRAF V600E mutation between January 1, 2015 and December 31, 2021 seen at the Ottawa Hospital Cancer Centre prior to the approval of cetuximab and encorafenib in Canada. Demographic, clinical, and cancer characteristics were collected from the medical records. Outcomes of interest included overall survival (OS) and time to next therapy (TNT).</div></div><div><h3>Results</h3><div>71 patients were included. The median age was 69 years, 37 (52 %) patients were females, and 19 (27 %) were mismatch repair deficient (dMMR). Median OS was 12.9 months with 21 (30 %) patients living greater than 2-years. Signet ring histology (HR=7.27, <em>p</em> &lt; 0.001), peritoneal metastasis (HR=2.29, 0.003), distant lymphatic metastasis (HR=2.70, <em>p</em> &lt; 0.001), brain metastasis (HR=2.86, <em>p</em> &lt; 0.048) and metastatectomy (HR=0.17, <em>p</em> &lt; 0.001) were associated with OS. Forty-six (65 %) patients received first-line systemic therapy, 14 (20 %) second-line and 2 (3 %) third-line. Median duration of therapy was 8.5 months for first-line, 5.5 months for second-line and 1.5 months for third-line.</div></div><div><h3>Conclusion</h3><div>Real world data demonstrates that patients with BRAF-V600E mCRC have poor clinical outcomes with traditional systemic therapies. Only a minority of patients received second- or third-line systemic treatments, highlighting the importance of ongoing research evaluating incorporation of targeted therapy in first-line treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100896"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole exome sequencing of low risk endometrial cancer patients with isolated local recurrences","authors":"Shuhua Zheng,&nbsp;Yirong Liu,&nbsp;Paul D. Kinkopf,&nbsp;Amulya Yalamanchili,&nbsp;Jonathan B. Strauss,&nbsp;Eric D. Donnelly","doi":"10.1016/j.ctarc.2025.100890","DOIUrl":"10.1016/j.ctarc.2025.100890","url":null,"abstract":"<div><h3>Introduction</h3><div>A small proportion of clinicopathologically low-risk endometrial cancer (EC) patients who omitted adjuvant radiotherapy (RT) may subsequently develop a local recurrence. Molecular profile for those clinically low-risk yet recurred EC patients is unavailable.</div></div><div><h3>Methods</h3><div>A total of 442 EC patients treated from 2014 to 2020 at Northwestern Memorial Hospital were studied. Among them, 28 patients clinically low risk or low-intermediate risk per GOG-99 criteria developed an isolated local recurrence after hysterectomy, bilateral salpingo-oophorectomy, and omitted RT. Whole exome sequencing (WES) was performed on 22 patients whose pathologic specimen were retrievable.</div></div><div><h3>Results</h3><div>The majority of the cases studied were molecularly No Specific Molecular Profile (NSMP) cohort (91%). We identified <em>CTNNB1, FGFR2, PTEN</em>, and <em>KRAS</em> as the most frequently altered pathogenic or likely pathogenic genes with 5 (22.7%), 5 (22.7%), 4 (18.2%), and 3 (13.6%) out of 22 patients carrying these alterations, respectively. <em>TP53</em> somatic alterations were identified in 2 (9.1%) out of 22 cases. Analysis of The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma (TCGA-UCEC) dataset identified 53 EC patients with pathologically Grade 1 molecularly NSMP cohort. Within this cohort, <em>CTNNB</em>1 alterations were identified in 31 patients (58%) and prognosticated worse progression free survival (<em>p</em>&lt;0.05).</div></div><div><h3>Conclusion</h3><div>NSMP molecular group constitutes the majority of clinically low-risk EC patients with isolated local recurrences. The <em>CTNNB1</em> alteration was validated as a biomarker in prognostication in this independent cohort and may help guide adjuvant treatment decisions.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100890"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative smart biosensors for cancer theranostics: A new frontier in detection, diagnosis, and beyond","authors":"Archna Dhasmana ,&nbsp;Ayushi Santhanam ,&nbsp;Khushi Dhasmana ,&nbsp;Sumira Malik ,&nbsp;Subham Preetam","doi":"10.1016/j.ctarc.2025.100911","DOIUrl":"10.1016/j.ctarc.2025.100911","url":null,"abstract":"<div><div>Cancer is still a major health concern worldwide, requiring ongoing improvements in methods of diagnosis and treatment. During the past decade, smart biosensors have become essential instruments in cancer theranostics, improving diagnosis accuracy, tracking treatment efficacy, and customizing patient care. This review thoroughly investigates how smart biosensors have revolutionized the field of cancer. The potential of major technical advancements, such as wearable technology, microfluidic platforms, and sensors based on nanomaterials to identify cancer biomarkers with high sensitivity and specificity is investigated. A detailed discussion is held regarding clinical applications that include early diagnosis, real-time monitoring of therapy responses, and support for personalized medicine techniques. Future directions targeted at optimizing the therapeutic utility of smart biosensors in oncology are also examined, along with issues pertaining to regulatory routes and clinical translation hurdles. This study highlights the potential of smart biosensors to transform cancer treatment, bringing in a new era of precision medicine and better patient outcomes by combining insights from multiple viewpoints.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100911"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deterioration of performance status before administration of chemotherapy as a prognostic factor in untreated advanced non-small cell lung cancer","authors":"Kenju Ando,&nbsp;Hirotsugu Kenmotsu,&nbsp;Yuichiro Nishibori,&nbsp;Akiko Tamura,&nbsp;Suguru Matsuda,&nbsp;Meiko Morita,&nbsp;Motoki Sekikawa,&nbsp;Kosei Doshita,&nbsp;Keita Miura,&nbsp;Hiroaki Kodama,&nbsp;Michitoshi Yabe,&nbsp;Noboru Morikawa,&nbsp;Yuko Iida,&nbsp;Nobuaki Mamesaya,&nbsp;Haruki Kobayashi,&nbsp;Ryo Ko,&nbsp;Kazushige Wakuda,&nbsp;Akira Ono,&nbsp;Tateaki Naito,&nbsp;Haruyasu Murakami,&nbsp;Toshiaki Takahashi","doi":"10.1016/j.ctarc.2025.100915","DOIUrl":"10.1016/j.ctarc.2025.100915","url":null,"abstract":"<div><h3>Introduction</h3><div>The prognostic impact of changes in performance status (PS) of untreated patients with advanced non-small cell lung cancer (NSCLC) are not clear. This study aimed to evaluate the prognostic impact of acute PS deterioration in patients with untreated advanced NSCLC.</div></div><div><h3>Methods</h3><div>This study is a single center, retrospective, observational study. Patients with Stage IV NSCLC who were referred to our institution between January 2018 and March 2023 were retrospectively reviewed. Patients were divided into three groups: 1) patients with PS 0 or 1 at referral and the start of chemotherapy; 2) patients with PS 2 or worse at initial referral and the start of chemotherapy; and 3) patients with PS 0 or 1 at referral that deteriorated to PS 2 or worse at the start of chemotherapy. The prognoses of Groups 2 and 3 were compared with those of Group 1.</div></div><div><h3>Results</h3><div>A total of 373 patients were included: 321 in Group 1, 20 in Group 2, and 32 in Group 3. The median overall survival (OS) of Group 3 was shorter than that of Group 1 (9.3 vs. 27.1 months, hazard ratio [HR] 2.56, <em>p</em> &lt; 0.01). The median OS of Group 2 was also shorter than that of Group 1, although not as significant as in Group 3 (20.2 vs. 27.1 months, HR 1.68, <em>p</em> = 0.06). After adjusting for symptoms, liver and pericardial metastases were associated with PS deterioration in multivariate analysis.</div></div><div><h3>Conclusion</h3><div>Among patients with untreated advanced NSCLC, acute PS deterioration before chemotherapy administration was associated with poor prognosis.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100915"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of immunotherapy in real-world patients with advanced non-small cell lung cancer","authors":"Na Yin ,&nbsp;Ruihan Yang,&nbsp;Xiangliang Liu,&nbsp;Xiao Chen","doi":"10.1016/j.ctarc.2025.100908","DOIUrl":"10.1016/j.ctarc.2025.100908","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;The aim of this study was to explore the predictors of immunotherapy efficacy for advanced non-small cell lung cancer (NSCLC) in the real world and to analyze the clinical efficacy and safety of patients receiving immunotherapy for advanced NSCLC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Clinical pathological data from patients diagnosed with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) were collected. Survival analysis and differential efficacy comparison of progression-free survival (PFS) was performed using the Kaplan-Meier method and Log-rank test. Univariate and multivariate analyses of PFS and objective response rate (ORR) were performed by Cox proportional risk regression models and logistic regression models to explore influence factors associated with the prognosis of immunotherapy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;&lt;strong&gt;Results&lt;/strong&gt;&lt;/h3&gt;&lt;div&gt;(1) Overall, the median PFS (median PFS, mPFS) for 237 patients was 11.3 months (range: 8.5-14.1), the ORR was 55.7 %. Univariate and multivariate analyses of PFS in the overall population found that age ≥65 years, Eastern Cooperative Oncology Group (ECOG) physical status (PS) score of 0-1, clinical stage III, absence of liver metastases, immunotherapy combined with chemotherapy and prognostic nutritional index (PNI) ≥47.8 were independent predictors of longer PFS in immunotherapy-advanced NSCLC. Univariate and multifactorial logistic regression analysis of ORR in 237 patients suggested that ECOG PS score, number of ICI lines and prognostic nutritional index (PNI) were independent influence factors of ORR.&lt;/div&gt;&lt;div&gt;(2) In the \"stage IV, first-line, ECOG PS 0-1\" subgroup, 106（106/237）patients had an mPFS of 10.9 months (range: 9.6-12.2) and an ORR of 59.4 %. Univariate and multivariate analyses of PFS in subgroups found that liver metastases, immunotherapy combined with chemotherapy and PNI were independent influencers of PFS. A univariate analysis of ORR found that only High-PNI was associated with longer PFS.&lt;/div&gt;&lt;div&gt;(3) Additional factors affecting the efficacy were explored. A subgroup analysis among 64 (64/237) patients with accessible programmed death-ligand 1 (PD-L1) expression levels showed a trend towards a PFS benefit in patients with PD-L1 tumor cell proportion score (TPS) ≥ 50 % and TPS &lt; 1 % compared to patients with PD-L1 TPS &lt; 1 % (p=0.196); A subgroup analysis among 91 (91/237) patients with traceable genetic test results showed that patients with positive driver genes (KRAS/MET/RET/HER2/EGFR/ALK) had a shorter PFS than patients with negative driver genes (HR=1.712, 95 % CI: 0.994-2.947, p=0.048); Subgroup analyses of efficacy assessment showed significantly prolonged PFS in patients with an initial or best outcome assessment of complete response (CR) or partial remission (PR) compared with stable disease (SD) or progressive disease (PD) (P &lt; 0.001).&lt;/div&gt;&lt;div&gt;(4) Immune-related adverse events (irAEs) requiring pharmacological interventi","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100908"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between p53 protein and ER, PR status in breast cancer tissue","authors":"Fang Zhang","doi":"10.1016/j.ctarc.2025.100895","DOIUrl":"10.1016/j.ctarc.2025.100895","url":null,"abstract":"<div><div>The aim of the present study was to investigate the protein expression levels of p53 in breast cancer tissues and analyze the relationship between the increased protein expression levels of p53 and the status of the estrogen receptor (ER) and progesterone receptor (PR). A total of 137 patients with breast cancer admitted to the General Surgery Department of the People's Liberation Army General Hospital from June to October 2023 were selected for inclusion in the present study and the expression levels of p53, ER and PR in cancer tissues were detected using immunohistochemistry. According to postoperative pathological results, patients were divided into ER positive negative groups and PR positive negative groups. Chi-squared tests used to analyze the difference in the protein expression levels of p53 between the ER positive and negative groups and the PR positive and negative groups. Additionally, the relationship between the protein expression levels of p53 in breast cancer tissue with patient age, the longest tumor diameter, tumor TNM stage, axillary lymph node status and histological subtype were analyzed. The protein expression levels of p53 in the ER positive and negative groups was 38.27 and 66.07 %, respectively, and the difference was statistically significant.The protein expression levels of p53 in the PR positive and negative groups was 42.27 and 67.50 %, respectively, and the difference was statistically significant. The protein expression levels of p53 in breast cancer tissue was not significantly associated with patient age, the longest tumor diameter, tumor TNM stage and histological subtype. But it was related to the status of axillary lymph nodes, the difference was statistically significant. In conclusion, the protein expression levels of p53 in breast cancer tissues were negatively correlated with the expression of ER and PR, which could be used to potentially provide clinical guidance for the prognosis of patients with breast cancer and improve the diagnosis and treatment of these patients in the future.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100895"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143641667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain","authors":"Antonio Calles ,&nbsp;Mirian Alonso ,&nbsp;Paloma Martín-Martorell ,&nbsp;Ana Gómez ,&nbsp;Javier de Castro ,&nbsp;Maite Martínez-Aguillo ,&nbsp;Anna Estival ,&nbsp;Joaquin Mosquera ,&nbsp;Natividad Martínez-Banaclocha ,&nbsp;Margarita Majem ,&nbsp;Roxana Reyes ,&nbsp;Eider Azkona ,&nbsp;Ana Laura Ortega ,&nbsp;Santiago Aguin ,&nbsp;Ana Santos ,&nbsp;Andrés Aguilar ,&nbsp;Marc Cucurull ,&nbsp;Ana Blasco ,&nbsp;Virginia Calvo ,&nbsp;Dolores Isla ,&nbsp;Javier Baena","doi":"10.1016/j.ctarc.2025.100905","DOIUrl":"10.1016/j.ctarc.2025.100905","url":null,"abstract":"<div><h3>Background</h3><div>Lorlatinib, a third-generation tyrosine kinase inhibitor (TKI), targets both ALK and ROS1 rearrangements in non-small cell lung cancer (NSCLC). It is approved for ALK-positive patients after progression on prior TKIs but lacks FDA or EMA approval for ROS1-positive NSCLC. This study evaluates lorlatinib's efficacy and safety in both ALK- and ROS1-positive patients through a compassionate use program in Spain.</div></div><div><h3>Methods</h3><div>We analyzed ALK-positive patients treated from November 2016 to February 2019 and ROS1-positive patients treated from November 2016 to March 2021. Eligible patients had Stage IV NSCLC with confirmed ALK or ROS1 rearrangements and prior TKI therapy. For ALK-positive patients, at least two prior TKIs were required if crizotinib was used first. For ROS1-positive patients, prior crizotinib was required.</div></div><div><h3>Results</h3><div>In 61 ALK-positive patients, 59 % had brain metastasis, and 85.2 % received at least two prior ALK TKIs. The overall response rate (ORR) was 32.8 %, with a median progression-free survival (PFS) of 11.2 months. Intracranial ORR was 47.6 %, with higher efficacy in patients with evaluable brain metastasis. In patients with 1, 2, or ≥3 lines of previous TKIs, we observed a median PFS of 15.1, 11.1 and 7.6 months, respectively. Among 42 ROS1-positive patients, 59 % had brain metastasis, and 61.9 % received ≥2 prior therapies. The confirmed ORR was 47.6 %, with 16.7 % complete responses. Median PFS was 10 months. Patients receiving crizotinib alone had a median PFS of 10 months, while those with two prior TKIs had a median PFS of 8.5 months. Intracranial response was 44.4 %, rising to 57.1 % in patients evaluable with brain metastasis. No new safety signals were observed.</div></div><div><h3>Conclusion</h3><div>Lorlatinib demonstrated consistent efficacy and manageable safety in both ALK- and ROS1-positive NSCLC patients treated under the compassionate use program in Spain. These real-world findings support its use as an effective treatment option in heavily pretreated patients.</div></div><div><h3>MicroAbstract</h3><div>We evaluated the efficacy and safety of lorlatinib in <em>ALK</em>- and <em>ROS1</em>-positive NSCLC patients within a compassionate use program in Spain. Among 61 <em>ALK</em>-positive patients, including 59 % with brain metastasis and 85.2 % treated with at least 2 prior ALK TKIs, lorlatinib achieved a confirmed overall response rate (ORR) of 32.8 % and a median progression-free survival (PFS) of 11.2 months. In 42 <em>ROS1</em>-positive patients previously treated with crizotinib, lorlatinib showed an ORR of 47.6 % and a median PFS of 10 months, confirming its clinical activity despite the lack of FDA or EMA approval for this indication.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100905"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis","authors":"Marco Galvez-Nino ,&nbsp;Katia Roque ,&nbsp;Rossana Ruiz ,&nbsp;Fernando Namuche ,&nbsp;Victor Paitan ,&nbsp;Tulio Arrese ,&nbsp;Jorge Zegarra ,&nbsp;George Oblitas ,&nbsp;Lisde Gonzalez ,&nbsp;Lorenzo Maco ,&nbsp;Maria del Pilar Cabrera ,&nbsp;Roberto Coello ,&nbsp;Jose Luis Portugal del Pino ,&nbsp;Juan Carlos Ezquerra ,&nbsp;Rodolfo Perez Roca ,&nbsp;Ofelia Coanqui ,&nbsp;Natalia Valdiviezo ,&nbsp;Mivael Olivera ,&nbsp;Tatiana Vidaurre ,&nbsp;Alfredo Aguilar Cartagena ,&nbsp;Luis Mas","doi":"10.1016/j.ctarc.2025.100906","DOIUrl":"10.1016/j.ctarc.2025.100906","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite osimertinib being the standard therapy for advanced EGFR T790M mutation positive NSCLC, in many Latin American countries, access to molecular testing and targeted therapies is limited, directly impacting patient outcomes. This study describes the real-world management and outcomes of Peruvian patients with advanced EGFR-mutated NSCLC who develop the T790M mutation.</div></div><div><h3>Methods</h3><div>We conducted a multicenter retrospective study including patients from nine Peruvian institutions, both public and private, who progressed to first-line EGFR TKI and developed T790M mutation, detected between January 2018 and December 2023. We evaluated demographic, clinico-pathological features and treatment data, including diagnostic pathway, treatment patterns, and survival outcomes.</div></div><div><h3>Results</h3><div>Seventy-eight patients were included; T790M was detected by liquid biopsy in 52.6 % of cases. Median time from progression to T790M detection was 59.5 days (7–244). Osimertinib was administered to 62.8 % of patients after detection, with a median initiation time of 42 days (1–104). Median overall survival (OS) from first-line treatment was 46.6 months for patients who received osimertinib, 23.9 months for those receiving other therapies, and 16.1 months for those without treatment (<em>p</em> = 0.001). Among osimertinib-treated patients, the objective response rate (ORR) was 59.2 %, with a median progression-free survival (PFS) of 15.8 months. Median OS from osimertinib initiation was 16.3 months, significantly longer than for patients receiving other treatments after T790M detection (9.7 months; <em>p</em> = 0.002).</div></div><div><h3>Conclusions</h3><div>This study confirms the real-world effectiveness of osimertinib in Peruvian patients with advanced EGFR T790M positive NSCLC and highlights the importance of timely detection and access to targeted therapies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100906"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and pathological differences between early- and late-onset colorectal cancer and determinants of one-year all-cause mortality among advanced-stage patients: a retrospective cohort study in Medellín, Colombia","authors":"Álvaro Esteban Ruiz Grajales ,&nbsp;Manuela María Orozco Puerta ,&nbsp;Senshuang Zheng ,&nbsp;Geertruida H. de Bock ,&nbsp;Juan Camilo Correa Cote ,&nbsp;Esteban Castrillón Martínez","doi":"10.1016/j.ctarc.2024.100797","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100797","url":null,"abstract":"<div><h3>Objective</h3><p>To identify the differences between early- (EOCRC) and late-onset colorectal cancer (LOCRC), and to evaluate the determinants of one-year all-cause mortality among advanced-stage patients.</p></div><div><h3>Methods</h3><p>A retrospective cohort study was carried out. CRC patients ≥ 18 years old were included. Chi-Square test was applied to compare both groups. Uni- and multivariate regressions were performed to evaluate the determinants of one-year all-cause mortality in all advanced-stage patients regardless of age of onset.</p></div><div><h3>Results</h3><p>A total of 416 patients were enrolled; 53.1 % were female. Ninety cases (21.6 %) had EOCRC and 326 (78.4 %) had LOCRC. EOCRC cases were predominantly sporadic (88.9 %). Histology of carcinoma other than adenocarcinoma (<em>p</em> <em>=</em> 0.044) and rectum tumors (<em>p</em> <em>=</em> 0.039) were more prevalent in EOCRC. LOCRC patients were more likely to have smoking history <em>(p</em> &lt; 0.001) and right colon tumors (<em>p</em> = 0.039). Alcohol consumption history (odds ratio [OR]: 3.375, 95 %CI: 1.022–11.150) and stage IV (OR: 12.632, 95 %CI: 3.506–45.513) were associated with higher one-year all-cause mortality among advanced-stage patients, the opposite was noted with left colon tumors (OR: 0.045, 95 %CI: 0.003–0.588).</p></div><div><h3>Conclusion</h3><p>EOCRC was predominantly sporadic and had more cases of uncommon histological subtypes and rectal tumors. LOCRC was characterized by a higher prevalence of smoking history. Multivariate regression revealed an association between higher one-year all-cause mortality and alcohol consumption history and stage IV in advanced-stage patients. CRC exhibited differences based on age of onset. The evaluated factors associated with CRC mortality provide valuable insights for healthcare professionals, emphasizing the importance of adequate clinical assessment and early CRC diagnosis.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100797"},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000091/pdfft?md5=6da1553e1727aa40e30c374c36841037&pid=1-s2.0-S2468294224000091-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139744024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}